Drug Trial Radar · NCT03782207
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,756
Actual
Start
Feb 7, 2019
Primary completion
Jul 31, 2026
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 20, 2018
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-interventional, multi-country, multi-centre, multiple cohort prospective study, with retrospective collection of prior medical/treatment history data from medical records, designed to assess the real-world outcomes and safety of atezolizumab for indications in the existing label in the real world setting of routine clinical practice.
Conditions
- Urothelial Carcinoma
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Hepatocellular Carcinoma
Interventions
AtezolizumabDrug
Atezolizumab will be administered at the discretion of the treating physician per local guidelines and independently of participation in this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Index date up to approximately 6 years
- OS at 2 YearsTime frame: After index date up to 2 years
Locations
257 sites in 30 countries. Site status is shown where the registry gives one.
Hospital Universitario Austral
Buenos Aires, Argentina
Lucen S.A.
Buenos Aires, Argentina
Consultorio Privado Korbenfeld
CABA, Argentina
Hospital Italiano de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
Sanatorio Allende
Córdoba, Argentina
Sanatorio de la Mujer
Rosario, Argentina
Fundacion Koriza
Santa Rosa, Argentina
Klinikum Klagenfurt
Klagenfurt, Austria
Landesklinikum Krems
Krems, Austria
Salzkammergut-Klinikum Voecklabruck
Vöcklabruck, Austria
Klinikum Wels-Grieskirchen
Wels, Austria
AZ KLINA
Brasschaat, Belgium
AZ St Maarten Campus Leopoldstr
Mechelen, Belgium
CHU UCL Mont-Godinne
Mont-godinne, Belgium
AZ Oostende
Ostend, Belgium
AZ Delta (Campus Rumbeke)
Roeselare, Belgium
Sint Trudo Ziekenhuis
Sint-Truiden, Belgium
Beneficencia Portuguesa de Sao Paulo
São Paulo, São Paulo, Brazil
Complex Oncology Center Burgas
Burgas, Bulgaria
Multiprofile Hospital for Active Treatment Uni Hospital
Panagyurishte, Bulgaria
Umhat Dr Georgi Stranski
Pleven, Bulgaria
University Hospital Palmed
Plovdiv, Bulgaria
Complex Oncological Center - Plovdiv, EOOD
Plovdiv, Bulgaria
Complex Oncology Center - Plovdiv First Internal Chemotherapy Department
Plovdiv, Bulgaria
DDODIU-Plovdiv, EOOD
Plovdiv, Bulgaria
Complex Oncological Center-Ruse EOOD
Rousse, Bulgaria
Tokuda Hospital
Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD
Sofia, Bulgaria
MBAL Serdika EOOD
Sofia, Bulgaria
MHAT SofiaMed
Sofia, Bulgaria
Specialized Hospital for Active Cancer Treatment, Dr. Mark Antonov Markov - Varna Ltd
Varna, Bulgaria
Centro de Estudios Clínicos SAGA
Santiago, Chile
Angiografia del Occidente
Cali, Colombia
Fundacion Clinica Valle del Lili
Cali, Colombia
Hospital Pablo Tobon Uribe
Medellín, Colombia
Clinica ASTORGA
Medellín, Colombia
Clinical Hospital Centre Osijek
Osijek, Croatia
Klinicki Bolnicki Centar Split
Split, Croatia
Clinical Hospital Center Sestre Milosrdnice
Zagreb, Croatia
Clinical Hospital Centre Zagreb
Zagreb, Croatia
Showing 40 of 257 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.